文献速递基础与转化研究临床试验与 GCP

自体nTreg输注减少肾移植免疫抑制的I/IIa期临床试验

Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial.
PubMed 文献 · BMJ · 2020-10-21

本研究为研究者发起的单中心I/IIa期临床试验,评估肾移植后输注自体天然调节性T细胞(nTreg)的安全性、可行性及减少免疫抑制的潜力。11例活体肾移植受者接受nTreg输注并逐步减量至低剂量他克莫司单药治疗,与9例参考组比较。结果显示nTreg输注安全可行,73%患者实现稳定单药免疫抑制,3年移植物存活率100%。

要点

  • 肾移植后输注自体nTreg安全可行,无剂量限制毒性。
  • 73%的nTreg组患者实现稳定单药免疫抑制,显著高于参考组。
  • nTreg组与参考组3年移植物存活率均为100%,安全性相似。

核心结论

  • 肾移植受者输注自体nTreg安全可行,且可实现免疫抑制减量至单药治疗。
  • 结果支持进一步评估Treg疗效,并为下一代nTreg方法开发奠定基础。

研究设计与样本

  • 研究者发起的单中心nTreg剂量递增I/IIa期临床试验(ONEnTreg13)。
  • 受者为活体肾移植受者(nTreg组n=11,参考组n=9)。
  • nTreg产品于肾移植后7天单次静脉输注,剂量为0.5、1.0或2.5-3.0×10^6细胞/kg体重。
  • 随后逐步将三联免疫抑制减量至低剂量他克莫司单药治疗至第48周。

主要发现

  • 所有患者均可从移植前两周采集的40-50 mL外周血中制备出产量、纯度和功能足够的nTreg产品。
  • 三个nTreg剂量递增组均未出现剂量限制毒性。
  • nTreg组和参考组3年移植物存活率均为100%,临床和安全性特征相似。
  • nTreg组11例中8例(73%)实现稳定单药免疫抑制,参考组仍维持标准双药或三药免疫抑制(P=0.002)。
  • 机制上,常规T细胞活化减少,nTreg在体内从多克隆T细胞受体库转变为寡克隆库。

关键数值与推荐

  • 主要临床和安全性终点通过第60周复合终点评估,并进一步随访3年。
  • 复合终点包括活检证实的急性排斥反应发生率、nTreg输注相关不良事件及过度免疫抑制迹象。
  • nTreg组73%实现稳定单药免疫抑制,参考组0%,组间比较P=0.002。

临床怎么用

  • 肾移植后输注自体nTreg可作为减少长期免疫抑制的策略,但需进一步验证疗效。
  • nTreg产品制备需在移植前两周采集40-50 mL外周血,并确保产量、纯度和功能。
  • 治疗过程中需监测急性排斥反应、输注相关不良事件及过度免疫抑制迹象。

局限性

  • 本研究为单中心、小样本I/IIa期试验,结果需更大规模研究验证。
  • 原文未报告长期随访中感染、肿瘤等过度免疫抑制相关事件的具体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether reshaping of the immune balance by infusion of autologous natural regulatory T cells (nTregs) in patients after kidney transplantation is safe, feasible, and enables the tapering of lifelong high dose immunosuppression, with its limited efficacy, adverse effects, and high direct and indirect costs, along with addressing several key challenges of nTreg treatment, such as easy and robust manufacturing, danger of over immunosuppression, interaction with standard care drugs, and functional stability in an inflammatory environment in a useful proof-of-concept disease model. DESIGN: Investigator initiated, monocentre, nTreg dose escalation, phase I/IIa clinical trial (ONEnTreg13). SETTING: Charité-University Hospital, Berlin, Germany, within the ONE study consortium (funded by the European Union). PARTICIPANTS: Recipients of living donor kidney transplant (ONEnTreg13, n=11) and corresponding reference group trial (ONErgt11-CHA, n=9). INTERVENTIONS: CD4+ CD25+ FoxP3+ nTreg products were given seven days after kidney transplantation as one intravenous dose of 0.5, 1.0, or 2.5-3.0×106 cells/kg body weight, with subsequent stepwise tapering of triple immunosuppression to low dose tacrolimus monotherapy until week 48. MAIN OUTCOME MEASURES: The primary clinical and safety endpoints were assessed by a composite endpoint at week 60 with further three year follow-up. The assessment included incidence of biopsy confirmed acute rejection, assessment of nTreg infusion related adverse effects, and signs of over immunosuppression. Secondary endpoints addressed allograft functions. Accompanying research included a comprehensive exploratory biomarker portfolio. RESULTS: For all patients, nTreg products with sufficient yield, purity, and functionality could be generated from 40-50 mL of peripheral blood taken two weeks before kidney transplantation. None of the three nTreg dose escalation groups had dose limiting toxicity. The nTreg and reference groups had 100% three year allograft survival and similar clinical and safety profiles. Stable monotherapy immunosuppression was achieved in eight of 11 (73%) patients receiving nTregs, while the reference group remained on standard dual or triple drug immunosuppression (P=0.002). Mechanistically, the activation of conventional T cells was reduced and nTregs shifted in vivo from a polyclonal to an oligoclonal T cell receptor repertoire. CONCLUSIONS: The application of autologous nTregs was safe and feasible even in patients who had a kidney transplant and were immunosuppressed. These results warrant further evaluation of Treg efficacy and serve as the basis for the development of next generation nTreg approaches in transplantation and any immunopathologies. TRIAL REGISTRATION: NCT02371434 (ONEnTreg13) and EudraCT:2011-004301-24 (ONErgt11).

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Roemhild A, Otto NM, Moll G, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ. 2020. PMID: 33087345. doi:10.1136/bmj.m3734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。